Luke Halpern

1 week ago | pharmacytimes.com | Luke Halpern

Author(s):The expansion of pneumococcal vaccine recommendations would ultimately lead to economic and health benefits, especially for underserved populations. Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period.

1 week ago | pharmacytimes.com | Luke Halpern |Amy Duong

CommentaryVideoJune 20, 2025Author(s):,Amy Duong, PharmD, BCACP, highlights the importance of patient counseling and addressing logistical challenges in treating patients with chronic inflammatory demyelinating neuropathy (CIDP).

1 week ago | pharmacytimes.com | Luke Halpern

Remnant cholesterol (RC) is directly associated with a higher risk of developing chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD) in patients with type 2 diabetes (T2D)-related kidney disease, according to results from a meta-analysis published in Diabetes, Obesity and Metabolism.1Remnant Cholesterol’s Role in CKD PathogenesisCKD constitutes a vast global burden, with estimates of approximately 850 million individuals across the world suffering from the disease.

1 week ago | pharmacytimes.com | Luke Halpern

The FDA has approved tafasitamab-cxix (Monjuvi; Incyte) in combination with rituximab (Rituxan; Genentech) and lenalidomide (Revlimid; Bristol Myers Squibb) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL), according to a news release from Incyte.1 Positive Results From inMIND Trial Bolster Tafasitamab-Cxix Approval is based on positive results from the phase 3 inMIND clinical trial (NCT04680052), presented as a late-breaking abstract at the 2024 American...

1 week ago | pharmacytimes.com | Luke Halpern

Each year, the FDA approves dozens of novel medicines that have never before been approved or marketed in the United States. These drugs are critical to patient populations impacted, who before these approvals often lacked a standard of care treatment option for their disease. Particularly in oncology, novel drugs are being developed at a rapid pace, expanding treatment capabilities for millions of patients with a form of cancer.